- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02688374
A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers
18 de dezembro de 2017 atualizado por: GlaxoSmithKline
A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers
This is a randomized, open-label, single-dose, three-period, crossover, single-center comparative bioavailability (BA) study under fasting condition in Chinese healthy male adult participants with a history of cigarette smoking.
The participants will be admitted to the investigational clinic at least 38 hours before dosing and will remain domiciled until the completion of all study procedures at approximately 24 hours after dosing.
Three toothpastes (one is commercial non-medicated non-nicotine containing chewing gum and other two are nicotine containing gums) will be provided across the 3 treatment periods.
During each of the 3 treatment periods, participants will be under supervision in a non-smoking area and will abstain from smoking.There will be a total of at least 7 days and not more than 10 days (clinical furlough period) between treatment periods.
Twenty (20) blood samples will be collected for pharmacokinetic (PK) analysis at baseline and multiple time points following study drug administration.
The trial duration will be approximately 49 days and up to 55 days from screening to study end including the screening period.
Visão geral do estudo
Status
Concluído
Condições
Tipo de estudo
Intervencional
Inscrição (Real)
45
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Beijing, China, 100032
- GSK Investigational Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 45 anos (Adulto)
Aceita Voluntários Saudáveis
Sim
Gêneros Elegíveis para o Estudo
Macho
Descrição
Inclusion Criteria:
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing to complete the required assessments and the study.
- Chinese male participants between 18 and 45 years of age (inclusive) in general good physical health as judged by the Investigator.
- Normal vital signs as follows:
- Oral body temperature between 35.0 and 37.5 ºC (95 and 99.5 F) inclusive
- Supine systolic blood pressure between 90 and 140 mmHg inclusive
- Supine diastolic blood pressure between 55 and 90 mmHg inclusive
- Pulse rate between 50 and 100 beats per minute (bpm) inclusive
- History of cigarette smoking of at least 10 cigarettes per day continuously for the past 3 months prior to screening.
- Body weight ≥ 50 kg, Body Mass Index (BMI) between 19 and 28 at screening.
- Ability to communicate and comply with all study requirements including the study specific chewing and swallowing procedures.
Exclusion Criteria:-
- Use of other investigational drugs within 30 days or 10 half-lives of enrollment, whichever is longer.
- History of or known hypersensitivity to the study drug or excipients.
- Diagnosis of long QT syndrome or QTc > 450 msec for males at screening.
- Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance.
- History of malignancy or neoplastic disease of any organ system treated or untreated, orthostatic hypotension, cardiovascular disease, stroke, TIA, fainting or blackouts, clinically significant metabolic, pulmonary, neurological, hematological, autoimmune, psychiatric or endocrine disorders.. within the past 5 years prior to screening.
- Any evidence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, autoimmune, neurological, psychiatric, other diseases or other clinically significant laboratory findings at screening.
- Participant has used any medication within two weeks before first scheduled study drug administration or within less than 10 times the elimination half-life of the respective drug.
- Unable to comply with the chewing and/or swallowing rhythm requirements (> 5% deviation of the total counts over 30 minutes) after trying either one of the two training sessions for 3 times.
- CO > 12 ppm after at least 38 hours confinement period in clinics prior to first dosing.
- Participants reports consumption of any drug metabolizing enzyme inducing or inhibiting aliments, evidence of current alcohol abuse or reports consumption exceeding 35 g of pure alcohol per day.
- Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis, positive results in any of the virology tests for Human immunodeficiency virus (HIV)-Ab, Hepatitis C virus (HCV)-Ab, Surface antigen of the hepatitis B virus (HBs-Ag), and Tp-Ab.
- Participation in a previous clinical study with or without another investigational product and with ~470 ml blood drawn, or blood donation within the last 3 months prior to screening or previous enrollment into the current study.
- Vulnerable individual
- Inability to be venipuncture and/or tolerate venous access, unwilling to accept slight irritation of the throat and increased salivation due to nicotine gum administration.
- Unable or unwilling to discontinue the use or consumption of cigarette smoking, any nicotine containing products, Oral, local or topical pharmaceutical agents, consumption of caffeine/theophylline - containing products, grapefruit, Seville orange, orange, lemon, lime, apple, and pineapple, performance of unaccustomed strenuous physical exercise.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Outro: Treatment A:Treatment B:Treatment C
Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Outro: Treatment B:Treatment C:Treatment A
Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Outro: Treatment C:Treatment A:Treatment B
Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Outro: Treatment A: Treatment C:Treatment B
Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Outro: Treatment B:Treatment A: Treatment C
Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
Outro: Treatment C:Treatment B:Treatment A
Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum).
Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
|
Participants will be administered with 2 mg coated mint gum of Nicorette
Participants will be administered with 2 mg coated mint gum of Nicotinell
Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Area under the curve from time zero to last sampling time [AUC(0-t)]
Prazo: 2 days
|
AUC(0-t) will be calculated using the trapezoidal rule.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Area under the curve from time zero extrapolated to infinity [AUC(0-inf)]
Prazo: 2 days
|
The area under the plasma concentration versus time curve will be calculated from time 0 to infinity where AUC = AUClast + Clast/λz Clast is the concentration at the last measurable sampling time point and λz is the terminal elimination rate constant.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Maximum plasma concentration (Cmax)
Prazo: 2 days
|
Cmax will be obtained graphically from the plasma concentration over time profile.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Time to reach maximum plasma concentration (Tmax)
Prazo: 2 days
|
Tmax will be obtained graphically from the plasma concentration over time profile.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Termination rate constant (Lambda_z)
Prazo: 2 days
|
Lambda_z will be computed as the slope of the regression line of ln (C(t)) on time.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Elimination half life (t1/2)
Prazo: 2 days
|
T1/2 will be computed as T1/2 = 0.693/ λz.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Systemic clearance (CL/F)
Prazo: 2 days
|
CL/F will be calculated as the Dose/AUCinf, where Dose is the actual nicotine dose released.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Apparent volume of distribution (Vd/F)
Prazo: 2 days
|
Vd/F will be determined by the following equation: Vz/F = Dose/(lambda_z · AUCinf), where Dose is the actual nicotine dose released.
Twenty (20) blood samples will be collected at baseline and multiple timepoints following study drug administration.
|
2 days
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
11 de março de 2016
Conclusão Primária (Real)
12 de junho de 2016
Conclusão do estudo (Real)
12 de junho de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
18 de fevereiro de 2016
Enviado pela primeira vez que atendeu aos critérios de CQ
18 de fevereiro de 2016
Primeira postagem (Estimativa)
23 de fevereiro de 2016
Atualizações de registro de estudo
Última Atualização Postada (Real)
19 de dezembro de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
18 de dezembro de 2017
Última verificação
1 de dezembro de 2017
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Distúrbios induzidos quimicamente
- Transtornos Relacionados a Substâncias
- Transtorno do Uso de Tabaco
- Efeitos Fisiológicos das Drogas
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Agentes colinérgicos
- Estimulantes ganglionares
- Agonistas Nicotínicos
- Agonistas colinérgicos
- Nicotina
Outros números de identificação do estudo
- 204979
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .